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http://dx.doi.org/10.1016/j.ccell.2015.05.006SUMMARYUnsustained enzyme inhibition is a barrier to targeted therapy for cancer. Here, resistance to a class I PI3K
inhibitor in a model of metastatic breast cancer driven by PI3K and MYC was associated with feedback
activation of tyrosine kinase receptors (RTKs), AKT, mTOR, and MYC. Inhibitors of bromodomain and extra
terminal domain (BET) proteins also failed to affect tumor growth. Interestingly, BET inhibitors lowered PI3K
signaling and dissociated BRD4 from chromatin at regulatory regions of insulin receptor and EGFR family
RTKs to reduce their expression. Combined PI3K and BET inhibition induced cell death, tumor regression,
and clamped inhibition of PI3K signaling in a broad range of tumor cell lines to provide a strategy to overcome
resistance to kinase inhibitor therapy.INTRODUCTION
Small-molecule inhibitors of kinases of the PI3K pathway (PI3K,
AKT, mTOR) have therapeutic value in cancers that contain le-
sions in the PI3K pathway; however, many of the tumors with
mutations in the pathway are resistant to treatment (Bendell
et al., 2012; Elkabets et al., 2013; Janku et al., 2012; She et al.,
2008). Resistance to therapy has in some instances been traced
to short-lived inhibition of the pathway that is due to feedback
activation of the transcription of tyrosine kinase genes in the in-
sulin receptor, and EGFR and JAK families (Britschgi et al., 2012;
Chandarlapaty et al., 2011; O’Reilly et al., 2006; Rodrik-Outmez-
guine et al., 2011; Serra et al., 2011). Inhibitors of receptor tyro-
sine kinases (RTKs) can ameliorate feedback to restore lower
PI3K signaling, but this approach has its limitations since the
repertoire of receptors activated by feedback in any given tumor
is unpredictable. Resistance to PI3K inhibitors can also beSignificance
Activation of feedback loops following inhibition of PI3K/AKT
been associated with upregulation of RTKs. However, the repe
is not yet predictable, prompting the need for combination tre
We have found that combined PI3K and BET inhibition overco
durable blockage of the PI3K signal in many types of cancer,
These findings provide the rationale for combining kinase and
feedback activation of signaling pathways in several human cdemonstrated through amplification ofMYC andEIF4E and over-
expression of RSK kinases, all of which regulate protein transla-
tion (Ilic et al., 2011; Liu et al., 2011; Serra et al., 2013).
Members of the BET family of proteins (BRD2, BRD3, BRD4,
and BRDT) contain two tandem bromodomains that recognize
acetylated-lysine residues in nucleosomal histones, facilitating
the recruitment of transcriptional proteins to chromatin (Filippa-
kopoulos et al., 2010). Small-molecule inhibitors of BETs show a
wide range of activity in different types of cancer through their
ability to alter the epigenetic landscape by interfering with
BRD4, which is required for enhancer function and transcrip-
tional elongation (Delmore et al., 2011; Filippakopoulos et al.,
2010; Rahl et al., 2010). Pharmacological inhibition of BET pro-
teins has been shown to lower the expression of a variety of
genes that are crucial for cell lineage and viability in several types
of malignancy (Asangani et al., 2014; Bandopadhayay et al.,
2014; Cho et al., 2014; Dawson et al., 2011; Delmore et al.,, BRAF, and MEK/ERK can lead to drug resistance and has
rtoire of receptors activated by feedback in any given tumor
atments that would be applicable in multiple tumor settings.
mes feedback activation of the PI3K pathway and leads to
cell death, and regression of allografted mammary tumors.
epigenetic inhibitors to improve therapy through blocking
ancers.
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2011; Lockwood et al., 2012; Love´n et al., 2013; Segura et al.,
2013; Shi et al., 2014; Whyte et al., 2013; Zuber et al., 2011).
Mitogenic signaling through RTKs activates PI3K to activate
AKT andmTOR to enhanceMYCmRNA translation,MYCprotein
half-life, and MYC transcriptional activity (Gera et al., 2004; Yeh
et al., 2004; Zhu et al., 2008). Moreover, inhibition of PI3K
pathway kinases is able to lower MYC levels in some cellular
contexts, and it has been established that activation of this up-
stream kinase cascade is required for cell transformation by
MYC (Lynch et al., 2004). Phosphoinositide-3 kinase (PI3K) and
MYC are therefore arguably components of the same signaling
pathway that coordinate metabolic signals to increase cell prolif-
eration (Hay and Sonenberg, 2004). Activation of this pathway
occurs through mutation of its major nodes, including activating
mutations of PIK3CA, amplification of ERBB2, mutation of AKT1,
loss of function mutations of PTEN (Bader et al., 2005; Manning
and Cantley, 2007), and increased genomic copy number, muta-
tion, or chromosomal translocation of MYC (Soucek and Evan,
2010). Many of these mutations co-occur within the same tumor,
including PIK3CA and MYC in breast cancer (Liu et al., 2011).
Alteration of PI3K and MYC has long been known to cooperate
in cellular transformation (Zhao et al., 2003). The therapeutic
repercussion for such co-occurrence is high, because amplifica-
tion of Myc in mouse mammary tumors initiated with a Pik3ca
mutation renders them resistant to PI3K inhibition (Liu et al.,
2011). Here, using a metastatic breast cancer model driven by
mutations in PI3K and MYC that is resistant to PI3K inhibition,
we set out to identify a treatment strategy that overcomes resis-
tance to PI3K inhibition and then determined its effectiveness in
multiple tumor types and genetic contexts.
RESULTS
PI3K and MYC Pathways Cooperate in Mouse Mammary
Tumorigenesis
While studying the role of Myc in mouse mammary tumorigen-
esis using MMTV-Myc transgenic mice (Stewart et al., 1984),
we found absence of PTEN staining through immunohistochem-
istry (IHC) in70%ofMyc tumors, which was accompanied with
reduced PtenmRNA (Figures 1A–1C and S1A; Table S1). To test
the hypothesis that somatic activation of the PI3K pathway is a
critical step in the evolution of MMTV-Myc tumors we crossed
MMTV-Myc mice with conditional Pik3ca hotspot mutants
(H1047R or E545K) (Figures S1B–S1D) or Ptenflox/flox mice (Li
et al., 2002). Expression of the mutant Pik3ca or deletion of
Pten in alveolar and ductal mammary epithelial cells was driven
by Cre that was expressed from the Wap locus (Ludwig et al.,
2001) and was achieved through mating. Because of the differ-
ence in the onset of MMTV and Wap promoter activation,
this is a faithful ‘‘two-hit’’ model where deregulatedMyc expres-
sion is effective in virgin females and activation of the PI3K
pathway is pregnancy/lactation dependent.
In contrast to Myc overexpressing females, which developed
focal mammary tumors with a median tumor latency (T50) of
115 days after the first parturition, invasive carcinomas appeared
in MMTV-Myc;Pik3caE545K/+;WapCre (EK;Myc), MMTV-Myc;
Pik3caH1047R/+;WapCre (HR;Myc), MMTV-Myc;Ptenflox/+;WapCre
(Ptendel/+;Myc), and MMTV-Myc;Ptenflox/flox;WapCre (Ptendel/del;
Myc) animals (collectively referred to as PI3K;Myc) within838 Cancer Cell 27, 837–851, June 8, 2015 ª2015 Elsevier Inc.approximately 1 week after the first parturition (Figure 1A). A
requirement for a second pregnancy was recorded in only
3/21 EK;Myc, 1/18 HR;Myc, 2/13 Ptendel/+;Myc, and none of
the Ptendel/del;Myc females. Mammary tumors, which were
palpable in many PI3K;Myc animals soon after the delivery of
pups, could involve more than one gland and were multifocal.
Moreover, they were always associated with widespread mam-
mary intraepithelial neoplasia (Figure S1E).
Comparative histopathological analysis showed that the
PI3K;Myc tumors had largely retained features characteristic of
Myc-induced adenocarcinomas (Andrechek et al., 2009; Cardiff
et al., 1991), consistent with previous observations indicating
that the Myc phenotype is dominant in combination with other
oncogenes (Cardiff et al., 1991). Thus, all invasive tumors were
composed of large cells with amphophilic cytoplasm and giant,
highly pleomorphic nuclei containing prominent nucleoli ar-
ranged in solid nests with abortive ductal structures (Figure 1C).
PI3K;Myc tumors were strongly positive for the basal keratins 5
and 14 (CK5 and CK14), showed variable expression of the
luminal keratin 18 (CK18), and were negative for ERa and PR
(Figure S1F; Table S1). Pulmonary micrometastases, which
were strongly positive for CK5, were present in 85% of PI3K;
Myc tumors, suggesting that these tumors are competent to
metastasize soon after their establishment (Figure S1G). Inter-
estingly, loss of Pten expression in either Myc-only or Ptendel/+;
Myc and Ptendel/del;Myc tumors was associated with a predom-
inantly membranous p-AKT (S473) immunostaining, which was
not seen in EK;Myc and HR;Myc tumors (Figures 1B and 1C;
Table S1).
PI3K;Myc Tumor Cells Are Resistant to PI3K or BET
Inhibition
The extreme rapidity of PI3K;Myc tumor onset indicates that
activation of PI3K and MYC is sufficient to drive mammary
tumorigenesis in mice and suggested that inhibition of these on-
cogenes might be an effective way to treat these tumors. To
dissect dependence on PI3K and MYC and identify potential
mechanisms of intrinsic resistance to targeted therapy, we
used fresh tumor specimens to generate HR;Myc (MCCL-278)
and Ptendel/del;Myc (MCCL-357) cancer lines. These cell lines
were validated for elevated expression of MYC and expression
of the H1047R Pik3ca mutation or loss of PTEN expression,
respectively, and both were capable of growing mammary
tumors when injected into the mammary fat pad of immunocom-
promised mice (Figure 2A). Allografted tumors grew with
extreme rapidity, retained the same histological features,
showed the same pattern of p-AKT immunostaining, and were
highlymetastatic to the lungs of the recipient animals (Figure 2B),
suggesting that they shared the key features of the primary
tumors.
Recent work has established that effective inhibition of the
PI3K signal in tumors requires inactivation of both p110a and
p110b (Costa et al., 2015; Jia et al., 2008; Schwartz et al.,
2015; Torbett et al., 2008; Wee et al., 2008). We therefore treated
our mouse cancer cell lines for 5 days with 0.125–8 mM of GDC-
0941, a pan-class I PI3K inhibitor (Folkes et al., 2008), and exam-
ined the effects on cell growth using an in vitro proliferation
assay. MCCL-278 and -357 cells were highly resistant to GDC-
0941 and had half maximal growth inhibitory concentration
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Figure 1. PI3K Pathway Alterations and MYC Cooperate in Mouse Mammary Tumorigenesis
(A) Kaplan-Meier plots of tumor occurrence in cohorts of female mice driven by MMTV-Myc and PI3K pathway alterations. The number of mice per cohort is
shown in parentheses. T50 indicates median tumor latency. *p < 0.02.
(B) Scatter plot showing correlation of absence of PTEN and membranous p-AKT (S473) immunostaining in Ptendel/+;Myc, HR;Myc, andMycmouse tumors. For
scoring of immunoreactivity, see Supplemental Experimental Procedures.
(C) Representative sections showing H&E staining and PTEN and p-AKT (S473) immunostaining of mammary tumors in Myc, HR;Myc, Ptendel/+;Myc, and
Ptendel/del;Myc female mice.
Scale bars, 50 mm. See also Figure S1.(IC50) values of 2.47 or 4.8 mM, respectively. Residual phosphor-
ylation of AKT was detected at 24 hr, especially at low doses of
GDC-0941, and could account for the poor inhibitory effects of
cell growth at these doses (Figure 2C). We also detected a
dose-dependent downregulation ofMYC expression (Figure 2C),
likely as a result of reduced translation of Myc mRNA and/or
increased GSK3b-mediated phosphorylation of MYC on threo-
nine-58 that produces a signal for degradation (Gera et al.,
2004; Gregory et al., 2003).Among the genes that pharmacological inhibition of BET pro-
teins have been recently shown to suppress effectively, MYC
has been shown in several instances to be important for tumor
viability (Asangani et al., 2014; Filippakopoulos et al., 2010; Ilic
et al., 2011; Rahl et al., 2010; Segura et al., 2013; Zuber et al.,
2011). Because our model is in part driven by MYC, we set out
to examine the effects of BET proteins inhibition on cell growth
using two different small-molecule inhibitors, JQ1 (Filippako-
poulos et al., 2010) and MS417 (Zhang et al., 2012), at theCancer Cell 27, 837–851, June 8, 2015 ª2015 Elsevier Inc. 839
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Figure 2. PI3K;Myc Cells Are Resistant to PI3K and BET Single Inhibition
(A) Representative sections showing H&E staining and PTEN and p-AKT (S473) immunostaining in mammary tumors from MCCL-278 and -357 allografts. Scale
bars, 50 mm.
(B) Representative sections showing H&E staining and PTEN and p-AKT (S473) immunostaining of lung metastases in females with MCCL-278 and MCCL-357
allografted tumors. Scale bars, 50 mm.
(legend continued on next page)
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same dose range and time as above. Treatment of MCCL-278
and -357 cells with JQ1 or MS417 failed to inhibit their growth
despite lowering MYC protein by 24 hr at high doses (R4 mM)
of the drugs (Figures 2D and S2A). Both BET inhibitors at 1 mM
partially lowered Myc mRNA at 2 hr to a level that was consis-
tent with what we had observed at the protein level at 24 hr
(Figure S2B). Similarly, downregulation of MYC expression us-
ing the small hairpin RNA (shRNA) approach failed to block cell
growth (Figure S2C). Unexpectedly, BET inhibition lowered
AKT phosphorylation in a dose responsive manner, suggesting
an unknown role of BET proteins in the activation of AKT
(Figure 2D).
We next sought to test the effects of PI3K or BET inhibition
in SUM-159 cells, a human breast cancer cell line that is
mutant for PIK3CA, wild-type for PTEN, and has a focal ampli-
fication in the MYC locus (Fernandez et al., 2013). Similar to
the resistant PI3K;Myc mouse cells, SUM-159 cells were
resistant to either PI3K (GDC-0941 IC50 = 2.31 mM) or BET
(JQ1 IC50 > 8 mM) inhibition, and as was seen with the mouse
tumor lines, both inhibitors partially lowered AKT phosphoryla-
tion and MYC (Figure S2D). Collectively, these data suggest
that tumor cells with high MYC levels and concurrent activa-
tion of the PI3K pathway are intrinsically resistant to BET or
PI3K inhibition.
BET Inhibition Sensitizes PI3K;Myc Cells to GDC-0941
Treatment
To examine whether BET inhibition could increase the efficacy of
GDC-0941, we treated resistant cells with a fixed dose of GDC-
0941 and increasing doses of JQ1 or MS417. In the presence of
1 mM of GDC-0941, significant attenuation of cell growth was
accomplished with as low as 0.125 mMof either of the BET inhib-
itors (Figures 3A, 3B, and S3A). The same results were seen with
1 mM of JQ1 andR1 mM of GDC-0941 for both mouse cell lines
(Figure S3B). Comparison of cell density after 5 days of treatment
with 1 mM of GDC-0941 and increasing doses of JQ1 revealed
that at least 1 mMof both drugs was required to have a cytostatic
effect (Figure 3C). Indeed, treatment of MCCL-357 and SUM-
159 cells with 1 mM of GDC-0941 and MS417 led to increased
induction of cell death compared with what was achieved with
single drug treatments (Figure 3D).
Combined inhibition of multiple nodes in the PI3K pathway
has been shown to overcome resistance to kinase-specific
inhibitors (Chandarlapaty et al., 2011; O’Reilly et al., 2006;
Rodrik-Outmezguine et al., 2011; Serra et al., 2011). To examine
how PI3K/BET inhibition compares with other combinatorial
treatments, we treated PI3K;Myc mouse cells for 3 days with
1 mM of GDC-0941 and 1 mM of inhibitors against receptors of
the EGFR family, AKT, mTOR, dual PI3K/mTOR, or PARP.
JQ1 treatment sensitized both cell lines to GDC-0941 more
than any other inhibitor (inhibition of growth 88.5%–93.3%) or
any other inhibitor combination, underscoring the potency of
PI3K/BET combined inhibition (Figure 3E).(C) Proliferation analysis for MCCL-278 and MCCL-357 cells treated with the in
replicates. Western blot analysis for p-AKT (T308) and MYC after treatment with
(D) Proliferation analysis for MCCL-278 and MCCL-357 cells treated with the indi
Western blot analysis for MYC and p-AKT (T308) after treatment with the same d
See also Figure S2.BET Inhibition Blocks PI3K Pathway Reactivation after
GDC-0941 Treatment
To gain more insight into how combined PI3K/BET inhibition
leads to effective growth inhibition, we treated MCCL-278,
MCCL-357, and SUM-159 cells with JQ1, GDC-0941, or the
combination and harvested cells at multiple time points for up
to 32 hr. Treatment with JQ1 led to downregulation of the PI3K
pathway over time as measured by phosphorylation of AKT
and its downstream target PRAS40 aswell as amodest suppres-
sion of MYC (Figures 4A and S4A). On the other hand, GDC-0941
treatment inhibited phosphorylation of AKT and its downstream
substrates FOXO1/O3, GSK3b, and PRAS40 as well as the
mTOR substrate 4E-BP1 within 1 hr of treatment (Figures 4B
and S4B). However, maximal inhibition of the signaling was
only transient since phosphorylation started to rebound at
4–8 hr, indicating that the PI3K pathway was reactivated.
PI3K-dependent inhibition of MYC followed the same pattern
after treatment with GDC-0941, with reduced expression occur-
ring only at 1 hr, suggesting that it is modulated by the same
feedback loop. Remarkably, addition of a BET inhibitor interfered
with the rebound of AKT phosphorylation and consequently
attenuated reactivation of the downstream pathway all the way
to MYC for up to 32 hr in all three cell lines (Figures 4B and S4B).
Inhibition of PI3K or AKT has been shown to induce the tran-
scription and activation of multiple receptor tyrosine kinases
(RTKs) that reactivate the pathway (Chandarlapaty et al., 2011;
O’Reilly et al., 2006; Rodrik-Outmezguine et al., 2011; Serra
et al., 2011). Expression of several RTK proteins including
INSR, IGF1R, HER2, and HER3 was indeed induced after
1–8 hr of GDC-0941 treatment, and this phenomenon was mark-
edly blocked by JQ1 (Figures 4B and S4B). Upregulation of
mRNA levels for IGF1R and INSR was also documented at 2 hr
of treatment with GDC-0941. However, JQ1 treatment was
able to suppress the transcripts of these receptors and alleviate
their GDC-0941-mediated induction (Figure 4C).
To provide further evidence that activation of RTKs of the
EGFR and INSR families contributes to the escape from growth
inhibition due to treatment with GDC-0941, we used pharmaco-
logical inhibitors for EGFR/ERBB2 (Lapatinib) and IGF1R/INSR
(OSI-906). Both inhibitors were able to partially rescue reactiva-
tion of the PI3K signal and improve inhibition of growth of MCCL-
357 and SUM-159 cells after treatment with GDC-0941 (Figures
4D, 4E, and S4C). Triple drug treatment efficiently blocked PI3K
signal but failed to inhibit cell growth to the same extent as GDC-
0941/MS417 dual treatment, suggesting that additional targets
are contributing to the growth inhibitory effects of BET inhibition
(Figures 4D, 4E, and S4C).
To examine whether reactivation of the PI3K signal is depen-
dent on MYC, we treated control and MYC-knockdown MCCL-
357 cells with 1 mM of JQ1, GDC-0941, or their combination.
Partial re-activation of the PI3K pathway after treatment with
GDC-0941 for 32 hr and upregulation of INSR and IGF1R, but
not of HER2 and HER3, was still documented in these cellsdicated concentrations of GDC-0941. Data represent average ± SD of three
the same doses for 24 hr is also shown.
cated concentrations of JQ1. Data represent average ± SD of three replicates.
oses for 24 hr is also shown.
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Figure 3. BET Inhibition Sensitizes Resistant Cells to PI3K Inhibition
(A) Proliferation analysis of indicated cells treated with 1 mM of GDC-0941 and the indicated doses of JQ1. Data represent average ± SD of three replicates.
(B) Representative result showing the effects on growth of MCCL-357 cells after treatment with the indicated doses of JQ1, GDC-0941, or the combination at day
5 of treatment.
(C) Fold changes in average cell growth of indicated cells after treatment with 1 mMof GDC-0941 and the indicated doses of JQ1. Values > 1 indicate reduction of
total cell numbers.
(D) Indicated cells were treated with 1 mMof GDC-0941, MS417, or their combination for 3 days in the presence of 1.5 mMof DRAQ7. Apoptotic red counts at the
indicated time points were calculated using IncuCyte FLR object counting. Data were normalized to confluence and then to DMSO-treated samples and
represent average ± SD of three replicates.
(E) Heatmap showing % of inhibition of MCCL-278 and MCCL-357 cell growth after treatment with 1 mM of the indicated inhibitors for 3 days. Data represent
average of two replicates.
See also Figure S3.
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Figure 4. JQ1 Treatment Hinders Feedback Activation of the PI3K Pathway after GDC-0941 Treatment
(A) MCCL-357 and SUM-159 cells were treated with 1 mMof JQ1 for the indicated time points, and the phosphorylation status of AKT and PRAS40 as well asMYC
levels were assessed by western blot.
(B) Western blot analysis in MCCL-357 and SUM-159 cells treated with 1 mM of GDC-0941 with or without 1 mM of JQ1 for the indicated time points.
(C) Quantitative RT-PCR for mRNA levels of the indicated receptors in cells treated with 1 mM of GDC-0941 and/or JQ1 relative to DMSO-treated control cells.
Results were normalized to actin and error bars indicate ± SD of three independent experiments.
(D)MCCL-357 cells were grown in the presence of 0.5 mMof the indicated inhibitors except for OSI-906, whichwas dosed at 1 mM, and confluencewas calculated
for the indicated time points using phase-contrast images. Data represent average ± SD of three replicates.
(E) Western blot analysis in MCCL-357 cells treated with the same doses of the indicated inhibitors as in (D) for 48 hr.
See also Figure S4.
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where MYC levels were undetectable (Figure S4D). Together,
these data suggest that in MCCL-357 tumor cells BET inhibitors
are able to lower PI3K signaling and cooperate with GDC-0941
to inhibit feedback activation of IGF1R and INSR regardless of
MYC, but feedback activation of HER2 and HER3 requiresMYC.
Combined PI3K/BET Inhibition Blocks Reactivation of
the PI3K Signal in Diverse Cancer Models
To further explore the ability of BET inhibition to block PI3K
pathway reactivation after treatment with PI3K inhibitors in
human breast cancer, we compared SUM-159 to six additional
breast cancer cell lines that harbor mutations in PIK3CA or
PTEN but lack focal amplification ofMYC (Figure 5A). Treatment
with 0.5 mM of GDC-0941 successfully blocked phosphorylation
of AKT at 1 hr, but pathway reactivation as measured by phos-
phorylation of AKT, FOXO1/O3, PRAS40, and/or 4E-BP1 was
evident at 24 hr (Figure S5A). Upregulation of specific RTKs
was also evident at 24 hr in some of the cell lines, as was MYC
(Figures 5A and S5A). Addition of 0.5 mM of MS417 was capable
of blocking the GDC-0941-mediated induction of expression of
HER3, INSR, and IGF1R in the majority of the cells that were
tested (Figures 5A and S5A). Most importantly, the combined
PI3K/BET inhibition blocked AKT and mTORC1 reactivation in
all seven breast cancer cell lines examined (Figure S5A).
BET inhibitors have been shown to be effective via different
targets in a cell lineage-dependent manner (Love´n et al., 2013;
Whyte et al., 2013; Asangani et al., 2014; Lockwood et al.,
2012; Shi et al., 2014). To examine whether BET inhibition could
block PI3K pathway reactivation in other tumor models, we
extended our analysis to PIK3CA/PTENmutant cells from multi-
ple tumor types (colorectal carcinoma, ovarian carcinoma, pros-
tate carcinoma, and glioblastoma multiforme). Inhibition of PI3K
signal after treatment with GDC-0941 was sustained in HCT116
and U-87MG cells but was transient in the rest of the cells with,
for example, rebounding of phosphorylation of PRAS40 and/or
4E-BP1 at 24 hr (Figure S5A). Notably, combined BET/PI3K
inhibition clamped the PI3K signal and lowered the expression
of IGF1R and HER3 in all examined cells that expressed these
receptors (Figures 5A and S5A). However, combined treatment
lowered the expression of INSR (Figure 5A), EGFR, and HER2
(Figure S5B; data not shown) in some, but not all, cell lines, sug-
gesting that expression of these receptors is not always regu-
lated by BET proteins. As was seen in the human breast cancer
lines, upregulation of MYC was often seen after 24 hr of GDC-
0941, which was typically rescued by the addition of MS417.
Since expression of MYC was either barely detectable in some
of the cells (e.g., MCF7, MDA-MB-468, OVCAR-3, U-87MG,
and DBTRG-05MG) or was not successfully inhibited by combi-
nation treatment in some others (e.g., PC-3, SK-OV-3, IGROV1),
we hypothesize that MYC contributes to the regulation of the
PI3K signal through BET inhibition in a subset of human tumors
(Figure S5A).
Combined treatment resulted in increased inhibition of cell
growth compared with what was achieved by single drug treat-
ment in several different cell lines, and this was also accompa-
nied by increased induction of apoptosis (Figures 5B and 5C).
Moreover, concurrent treatment with Lapatinib, OSI-906, and
GDC-0941 was able to block reactivation of the PI3K signal in
BT-549 and RKO-1 cells as a result of treatment with GDC-844 Cancer Cell 27, 837–851, June 8, 2015 ª2015 Elsevier Inc.0941, suggesting that the feedback activation of receptors of
the insulin and EGFR families is at least partially responsible
for their growth in the presence of the PI3K inhibitor (Figures
S5C and S5D). Collectively, these results show that feedback
activation of signaling induced by PI3K inhibition can be attenu-
ated by targeting BRD4 and possibly other BET proteins in mul-
tiple cancer models and suggest that a co-treatment strategy
may be broadly effective in situations where feedback activation
limits the efficacy of therapy.
BET Inhibition Dissociates BRD4 from Regulatory
Regions of Multiple RTKs
BET inhibitors like JQ1 and MS417 have been shown to display
high affinity for both bromodomains in BET family members
(BRD2, 3, 4) relative to other bromodomain proteins and prevent
binding to acetylated histones and chromatin. To better under-
stand the molecular mechanism underlying the function of BET
inhibitors, we analyzed publicly available chromatin immunopre-
cipitation sequencing (ChIP-seq) data for BRD4 binding at
putative regulatory regions of multiple RTKs. Enriched BRD4
occupancy was present at conserved regions upstream the tran-
scriptional start site (TSS) of multiple RTKs (sites A) andMYC as
well as specific intronic regions (sites B) of IGF1R and INSR (Fig-
ures 6A, 6B, and S6A) in HeLa and HEK293T cells (Liu et al.,
2013). Increased BRD4 binding was also present at the same
sites in MM.1S cells, a multiple myeloma cell line (Love´n et al.,
2013), and this was dramatically reduced after treatment with
0.5 mM of JQ1 for 6 hr (Figures 6A, 6B, and S6A). Interestingly,
increased BRD4 binding that was susceptible to treatment with
JQ1 was documented exclusively after growth stimulation with
serum at putative regulatory regions of Her3 and Igf1r in NIH
3T3 cells (Kanno et al., 2014), suggesting that in certain contexts
regulation of expression of some BRD4 targets may be depen-
dent on specific mitogenic stimuli (Figure S6B).
To determine if RTKs are direct targets of BRD4 in our model,
we performed ChIP experiments in multiple cell lines using an
affinity-purified anti-Brd4 antibody. Primers upstream of the
TSS of IGF1R, INSR, HER3, and MYC as well as intragenic re-
gions for IGF1R and INSR, located in regions where enriched
BRD4 binding was present in MM.1S cells (sites A and B),
were used in ChIP-qPCR to detect the binding of BRD4.
Increased BRD4 occupancy compared with IgG control was
documented at these sites in BT-549, RKO-1, and PC-3 cells
as well as homologous regions inMCCL-357 cells, but no enrich-
ment was present in distinct intronic regions of IGF1R and INSR
(sites C) where BRD4 bindingwas absent inMM.1S cells (Figures
6C–6E and S6C). Treatment with 0.5 mM of MS417 for 6 hr effec-
tively inhibited BRD4 binding to most of these sites in BT-549,
RKO-1, and MCCL-357 cells in the presence or absence of
GDC-0941. In the case of PC-3 cells, MS417 was able to sup-
press induction of BRD4 binding after treatment with 0.5 mM of
GDC-0941 (Figure 6D). Inhibition of BRD4 binding after treat-
ment with a BET inhibitor correlated with reduced expression
of IGF1R and INSR in RKO-1, PC-3, and MCCL-357 cells (Fig-
ures 4C and S6D). Of note, BET inhibition failed to regulate
BRD4 binding at the promoter ofMYC in PC-3 cells (Figure S6E),
which is in accordance with what was previously observed with
MYCprotein in these cells (Figure S5A). These data identify RTKs
of the EGFR and insulin receptor families as direct targets of
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Figure 5. Combined PI3K/BET Inhibition Clamps PI3K Signal and Attenuates Cell Growth in Multiple Tumor Models
(A) Western blot analysis in cells treated with 0.5 mM of GDC-0941 and/or 0.5 mM of MS417 for the indicated time points. Dashed lines were drawn to highlight
induction of RTKs after treatment with GDC-0941.
(B and C) Cells were grown in the presence of 0.5 mM of the indicated inhibitors and 1.5 mM of DRAQ7. Confluence (B) was calculated using phase-contrast
images and apoptotic counts (C) using IncuCyte FLR object counting. Data represent average ± SD of three replicates.
See also Figure S5.
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BRD4 in several cancer models and strongly suggest that BET
inhibition can regulate the PI3K signal in cancer cells by blocking
BRD4 recruitment to regulatory regions of these receptors.
Combined PI3K/BET Inhibition Is Effective In Vivo
To test whether PI3K and BET inhibition would inhibit tumor cell
growth in vivo, we evaluated the effects of GDC-0941 and/or
MS417, which is known to be effective in mice (Shi et al.,
2014), in animals engrafted with MCCL-278 and MCCL-357 tu-
mors. Mice were treated with 100 mg/kg/day GDC-0941 and/
or 75 mg/kg/day MS417 until tumors in the vehicle-treated ani-
mals reached the allowed maximum tumor size. BET inhibition
resulted in modest inhibition of tumor growth for both allografted
cell lines, and this was accompanied by minimal suppression of
MYC and the PI3K signal (Figures 7A–7C). In a similar fashion,
treatment with GDC-0941 attenuated the growth of these
tumors but only partially inhibited PI3K and mTOR signaling
and failed to downregulate MYC. Importantly, mice treated
with the combination experienced further suppression of PI3K
andmTOR signaling andMYCprotein (Figure 7C). The dual treat-
ment was superior to any of the single treatments and resulted in
significant tumor shrinkage and tumor cell death as evidenced
by increased levels of cleaved caspase-3 (Figures 7A–7C).
DISCUSSION
Here, we use genetic data to demonstrate that sequential activa-
tion of MYC and PI3K is sufficient to drive tumorigenesis in mice,
and most likely in humans, where they tend to co-occur (Liu
et al., 2011). Moreover, we show that Pten expression is reduced
in the majority of tumors driven by MMTV-Myc, underscoring the
importance of PI3K pathway activation in the evolution of mouse
Myc tumors. Generating tumors with specific oncogenes has
allowed us to dissect dependence on these oncogenes and
identify mechanisms involved in the reduced efficacy of single
drug use. Our findings show that PI3K and MYC cooperate as
part of a single mitogenic signaling pathway to form cancers.
Effective treatment of these tumors in an allograft system
required an approach that targets multiple nodes in the pathway
to maintain downregulation of the PI3K signal (Figure 7D). One
relevant insight of these studies is that it can be inferred that if
the PI3K signal is clamped for a sufficient period of time, tumor
cell death can occur. The implication for therapy is that com-
bined treatment for several days to achieve maximal tumor cell
killing could be sufficient to have a beneficial anti-tumor effect
and would not have to be continuous. Although our findings
are promising, further work will be needed in additional models
and in human clinical trials to determine the ultimate efficacy of
combining PI3K and BET inhibitors and whether there will be a
sufficient therapeutic window.
Because of the importance of PI3K pathway activation,
multiple inhibitors targeting this pathway are currently underFigure 6. BET Inhibition Blocks BRD4 Binding at Regulatory Regions o
(A and B) Tracks show BRD4 binding across the IGF1R (A) and INSR (B) loci in the
and C indicate the regions where primers were designed to test for the binding o
(C–E) ChIP-qPCR analysis of BRD4 binding at the indicated sites in RKO-1 (C), P
their combination for 6 hr. Data represent average ± SD of two qPCR experimen
See also Figure S6.development (Martini et al., 2013). However, feedback activation
of tyrosine kinase receptors (Britschgi et al., 2012; Chandarla-
paty et al., 2011; O’Reilly et al., 2006; Rodrik-Outmezguine
et al., 2011; Serra et al., 2011) can account for intrinsic resistance
to PI3K inhibition. Alternatively, signals that activate MYC, such
as the WNT (Tenbaum et al., 2012), Notch (Muellner et al., 2011),
AKT (Zhu et al., 2008) or RSK pathways (Serra et al., 2013; Zhu
et al., 2008) as well as MYC itself (Ilic et al., 2011; Liu et al.,
2011) or its downstream target eIF4E (Ilic et al., 2011), are all
able to confer resistance to PI3K inhibitors. Combining PI3K in-
hibitors with inhibitors against specific RTKs has been shown
to be efficacious in specific models but may have limited utility
because of difficulty in predicting the repertoire of receptors
that are activated by feedback and the problem of PI3K-inde-
pendent activation of MYC by amplification or other means.
On the basis of our results, a BET inhibitor could be more effec-
tive than a tyrosine kinase-specific inhibitor at clamping PI3K
reactivation by blocking the expression of multiple RTKs and
potentially other unknown factors that would otherwise lead to
reactivation of the PI3K pathway caused by GDC-0941. This
could involve INSR, IGF1R, EGFR, HER2, and HER3, which
were successfully inhibited by MS417 in some of the studied
cell lines, and receptors of the PDGF family that can also activate
the PI3K pathway. Finally, BET inhibitors have the advantage of
being able to reduce MYC function as a transcription and tran-
scription-elongation factor (Delmore et al., 2011; Rahl et al.,
2010), which could possibly overcome resistance due to MYC,
which we have shown can contribute to feedback activation of
HER2 and HER3 expression in some instances.
BET inhibitors affect the expression of a wide range of cancer-
relevant targets including MYC, estrogen receptor (Feng et al.,
2014), and multiple classes of kinases and other signaling
proteins. Because of their broad efficacy, they may be clinically
useful in other settings where activation of feedback loops plays
a role in intrinsic or acquired resistance to targeted therapy. For
instance, ERBB2+ breast cancer cells with acquired resistance
to an ERBB2/EGFR inhibitor through the activation of expression
of diverse kinases have their sensitivity restored with a BET
inhibitor, which was able to target kinases (ERBB3/FAK/EPH/
DDR1) contributing to resistance (Stuhlmiller et al., 2015). RAF
inhibitors can only transiently inhibit the ERK pathway as they
de-repress transcription of HER3 in thyroid tumor cells
(Montero-Conde et al., 2013) and EGFR in BRAF (V600E) mutant
colon tumor cells (Prahallad et al., 2012). Activation of RTKs has
been documented after MEK inhibition in breast tumor cells
resulting in ERK pathway reactivation (Duncan et al., 2012).
Therefore, it is possible that combined kinase and epigenetic
targeting in cancer can be a general strategy to circumvent
feedback-mediated resistance from inhibition of other kinases
besides PI3K.
In combination with PI3K inhibition, BET inhibition was able to
block all or some portion of PI3K signal reactivation in all thef RTKs in Multiple Tumor Models
indicated cells with or without treatment with 0.5 mMof JQ1 for 6 hr. Sites A, B,
f BRD4 in ChIP-qPCR experiments.
C-3 (D), and MCCL-357 (E) cells treated with 0.5 mM of GDC-0941, MS417, or
ts. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 7. Antitumor Efficiency of PI3K and BET Inhibition In Vivo
(A) MCCL-278 and MCCL-357 allografts were treated with GDC-0941, MS417, or their combination. Number of mice per arm is shown in parentheses, and error
bars indicate ± SD. The p values were calculated using Sidak’s multiple comparisons test.
(B) Representative tumors from mice (MCCL-278 left flank and MCCL-357 right flank) treated with the indicated drugs.
(C) MCCL-278 and MCCL-357 allografts were treated for 72 hr with the indicated drugs, at which point tumors were harvested and snap frozen. Effects of
treatments on MYC, markers of the PI3K pathway, and induction of cleavage of Caspase-3 as an indicator of apoptosis were assessed by western blot. Results
from two different animals per treatment group are shown here.
(D) A schematic representation of signaling responses to inhibition of PI3K and PI3K/BET combination.
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human and mouse tumor cells that were examined. The com-
bined use of BET and PI3K inhibitors may be useful in a setting
in whichMYC is or is not a driver oncogene because of the ability
of BET inhibitors to broadly inhibit feedback activation of the
PI3K pathway after treatment with a PI3K inhibitor through its
interaction with receptor gene chromatin. Our examination of
20 lines showed that the combination led to a sustained inhibition
of the PI3K and mTOR signals and tumor cell death in many of
the lines tested. Indeed, basal levels of MYC protein were very
low in several of the cells that were studied or BET inhibition
failed to inhibit BRD4 binding at the promoter of MYC or sup-
press its expression in some cell lines (e.g., PC-3), suggesting
that MYC itself was not required for the ability of BET inhibitors
to regulate RTK expression. Our findings reveal that regulation
of PI3K through BETs is a cancer cell protective feedback mech-
anism that can be exploited for therapy in a variety of tumor types
when feedback contributes to therapeutic resistance. Further
studies are necessary to determine the therapeutic benefit of
combining these inhibitors in a clinical setting.
EXPERIMENTAL PROCEDURES
Generation of Pik3caE545K/+ and Pik3caH1047R/+ Mice
To generate Pik3caE545K/+ and Pik3caH1047R/+ mice, we used site-directed
mutagenesis to introduce point mutations in codons 545 of exon 9 (E545K)
and 1047 of exon 20 (H1047R) and a DNA sequence in the upstream intronic
regions consisting of the following components: loxP site, splice acceptor
site, neomycin-resistance gene driven by the Pgk gene promoter, transcrip-
tional ‘‘stop’’ sequence (triple SV40 polyadenylation signal), and loxP site.
Both models were validated for proper expression of the mutated proteins
(see Supplemental Experimental Procedures and Figure S1). Experiments
involving mice were performed according to Columbia University and Mount
Sinai School of Medicine Institutional Animal Care and Use Committee
approved protocols.
Proliferation and Apoptosis Assays
Experiments were carried out in 48-well plates in triplicates. 5–10 3 103 cells
per well were grown in the presence of various doses of JQ1, MS417, and/or
GDC-0941 for 5 days and were treated with fresh drugs at day 3. At the indi-
cated time intervals, cells were washed once with PBS, stained with 0.05%
crystal violet in formalin at room temperature for 20–30 min, and washed again
twice with PBS before extracting the dye with 10% acetic acid. Plates were
then shaken on a microplate shaker at medium speed for at least 1 hr, and
the absorbance, corresponding to cell numbers attached on the plates,
was measured at 595 nm on a multi-well plate reader (Bio-Rad). Alternatively,
1–33 103 cells were seeded in 96-well plates in triplicates and drugged at the
indicated doses in the presence of 1.5 mMDRAQ7 (Cell Signaling #7406). Cells
were then monitored using the IncuCyte live cell imaging system (Essen
BioScience), which was placed in a cell culture incubator operated at 37C
and 5% CO2. Cell confluence was determined using calculations derived
from phase-contrast images. Apoptotic red counts were measured in an Incu-
Cyte FLR automated incubator microscope.
Establishment of Mouse Mammary Cancer Cell Lines
Tumor tissue was finely minced and cell aggregates were trypsinized for 10–
15 min. Trypsin was inactivated using regular mouse embryonic fibroblasts
(MEF) medium, and single cells were generated with mechanical pipetting.
Both MCCL-278 and MCCL-357 cell lines were cultured thereafter using
regular MEF medium and were routinely passaged twice a week. Cells were
tested negative for all tests of the Infectious Microbe PCR Amplification Test
(IMPACT).
Cell Infections
For Myc downregulation experiments, MISSION Lentiviral Transduction Parti-
cles were purchased from Sigma-Aldrich (clone IDs: TRCN0000-042514,
-042515, -234924, -234925, -234926) and used according to the manufac-turer’s instructions. Briefly, 105 cells were transduced with the viral particles
at a MOI = 20 along with a final concentration of 8 mg/mL polybrene. Cells were
selected with puromycin at 1 mg/ml for 10 days and then used immediately for
signaling and cell growth analysis.
In Vivo Treatment Studies
Approximately 6- to 8-week-old female nude mice (Taconic) were injected
subcutaneously with 0.5 3 106 MCCL-278 and 1 3 106 MCCL-357 cells in
MEF media in the left and right flank, respectively. Females bearing tumor
grafts were randomized in groups of seven to eightmice per groupwhen tumor
volumes reached 100 mm3 (MCCL-278) and 200 mm3 (MCCL-357). Ani-
mals were treated by oral gavage with GDC-0941 at 100 mg/kg/d (dissolved
in 10% DMSO, 5% Tween 20, 85% water) and/or by intraperitoneal injection
with MS417 at 75 mg/kg/d (dissolved in 10%HP-b-CD) for 8 days. Pharmaco-
dynamic measurements were performed after 72 hr of treatment. Tumor
volume was calculated as follows: tumor size (mm3) = (longer measurement
3 shorter measurement2) 3 0.5. Tumor sizes were recorded every other day
over the course of the studies.
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